CA2788761C - Sanglifehrin based compounds useful for treating viral infection caused by hcv, hbv or hiv - Google Patents

Sanglifehrin based compounds useful for treating viral infection caused by hcv, hbv or hiv Download PDF

Info

Publication number
CA2788761C
CA2788761C CA2788761A CA2788761A CA2788761C CA 2788761 C CA2788761 C CA 2788761C CA 2788761 A CA2788761 A CA 2788761A CA 2788761 A CA2788761 A CA 2788761A CA 2788761 C CA2788761 C CA 2788761C
Authority
CA
Canada
Prior art keywords
single bond
represented
following structure
bond
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2788761A
Other languages
English (en)
French (fr)
Other versions
CA2788761A1 (en
Inventor
Steven James Moss
Matthew Alan Gregory
Barrie Wilkinson
Christine Janet Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abliva AB
Original Assignee
Neurovive Pharmaceutical AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1002097.2A external-priority patent/GB201002097D0/en
Priority claimed from GBGB1006128.1A external-priority patent/GB201006128D0/en
Priority claimed from GBGB1101085.7A external-priority patent/GB201101085D0/en
Application filed by Neurovive Pharmaceutical AB filed Critical Neurovive Pharmaceutical AB
Publication of CA2788761A1 publication Critical patent/CA2788761A1/en
Application granted granted Critical
Publication of CA2788761C publication Critical patent/CA2788761C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
CA2788761A 2010-02-09 2011-02-09 Sanglifehrin based compounds useful for treating viral infection caused by hcv, hbv or hiv Expired - Fee Related CA2788761C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1002097.2A GB201002097D0 (en) 2010-02-09 2010-02-09 Novel compounds
GB1002097.2 2010-02-09
GB1006128.1 2010-04-13
GBGB1006128.1A GB201006128D0 (en) 2010-04-13 2010-04-13 Novel compounds
GB1101085.7 2011-01-21
GBGB1101085.7A GB201101085D0 (en) 2011-01-21 2011-01-21 Novel compounds
PCT/GB2011/050236 WO2011098809A1 (en) 2010-02-09 2011-02-09 Sanglifehrin based compounds

Publications (2)

Publication Number Publication Date
CA2788761A1 CA2788761A1 (en) 2011-08-18
CA2788761C true CA2788761C (en) 2018-05-29

Family

ID=43836693

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2788761A Expired - Fee Related CA2788761C (en) 2010-02-09 2011-02-09 Sanglifehrin based compounds useful for treating viral infection caused by hcv, hbv or hiv

Country Status (9)

Country Link
US (1) US9119853B2 (https=)
EP (1) EP2533784B1 (https=)
JP (1) JP5894935B2 (https=)
AU (1) AU2011214135B2 (https=)
BR (1) BR112012019866A8 (https=)
CA (1) CA2788761C (https=)
ES (1) ES2541853T3 (https=)
MX (1) MX2012008873A (https=)
WO (1) WO2011098809A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201008123D0 (en) * 2010-05-17 2010-06-30 Biotica Tech Ltd Novel compounds
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
GB201118334D0 (en) 2011-10-24 2011-12-07 Biotica Tech Ltd Novel dosage form
AU2017361856A1 (en) 2016-11-18 2019-05-23 Neurovive Pharmaceutical Ab Use of sanglifehrin macrocyclic analogues as anticancer compounds
BR112021012057A2 (pt) * 2018-12-21 2021-10-19 Revolution Medicines, Inc. Compostos que participam de ligação cooperativa e usos dos mesmos
TW202132316A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
CA3194067A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Ras inhibitors
KR20240017811A (ko) 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. 암의 치료를 위한 ras 억제제
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
ES2244001T3 (es) 1996-07-05 2005-12-01 Biotica Technology Limited Eritromicinas y procedimiento para su preparacion.
GB9814622D0 (en) 1998-07-06 1998-09-02 Biotica Tech Ltd Polyketides,their preparation,and materials for use therein
AU2006259348B2 (en) 2005-06-17 2010-07-22 Novartis Ag Use of sanglifehrin in HCV
US8450281B2 (en) 2007-01-04 2013-05-28 Debiopharm S.A. Non-immunosuppressive cyclosporin for treatment of Ullrich congenital muscular dystrophy
CN102224242B (zh) 2008-09-24 2014-09-24 中国科学院上海有机化学研究所 新基因簇
JO3063B1 (ar) 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه

Also Published As

Publication number Publication date
BR112012019866A2 (pt) 2017-07-11
MX2012008873A (es) 2012-11-22
AU2011214135B2 (en) 2014-07-31
CN102770139A (zh) 2012-11-07
BR112012019866A8 (pt) 2017-12-26
US20120295841A1 (en) 2012-11-22
EP2533784B1 (en) 2015-04-22
WO2011098809A1 (en) 2011-08-18
EP2533784A1 (en) 2012-12-19
JP2013518923A (ja) 2013-05-23
US9119853B2 (en) 2015-09-01
JP5894935B2 (ja) 2016-03-30
CA2788761A1 (en) 2011-08-18
ES2541853T3 (es) 2015-07-27
AU2011214135A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
CA2788761C (en) Sanglifehrin based compounds useful for treating viral infection caused by hcv, hbv or hiv
AU2012235880B2 (en) Macrocyclic compounds and methods for their production
WO2011098808A1 (en) Sanglifehrin based compounds
WO2011098805A1 (en) Sanglifehrin based compounds
WO2011144924A1 (en) Amine or amid analogues of sanglifehrin
CN102770139B (zh) 基于Sanglifehrin的化合物
AU2011346823B2 (en) Sanglifehrin derivatives and methods for their production
Class et al. Patent application title: Macrocyclic Compounds and Methods for Their Production Inventors: Steven James Moss (Cambridge, GB) Matthew Alan Gregory (Cambridge, GB) Matthew Alan Gregory (Cambridge, GB) Barrie Wilkinson (Cambridge, GB) Assignees: NeuroVive Pharmaceutical AB
HK1189237B (en) Macrocyclic compounds and methods for their production
HK1189236B (en) Macrocyclic compound and methods for its production

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160128

MKLA Lapsed

Effective date: 20210209